Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

164.30 -3.25 (-1.94%)

Streaming Delayed Price Updated: 3:03 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

56 57 Next >

10 Health Care Stocks Whale Activity In Today's Session ↗

October 24, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

15 Analysts Have This to Say About Biogen ↗

October 24, 2022

Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:

Via Benzinga

$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today ↗

October 24, 2022

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.47% on an annualized basis producing an average annual return of 9.66%. Currently, Biogen has a market capitalization of...

Via Benzinga

Earnings Preview: Biogen ↗

October 24, 2022

Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Tuesday, 2022-10-25. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report an...

Via Benzinga

Biogen To Report Q3 Earnings: Here's What To Expect ↗

October 21, 2022

Biogen will report third-quarter 2022 results on Oct 25, before market open.

Via Talk Markets

3 Alzheimer's Therapy Stocks to Invest in ↗

October 21, 2022

Alzheimer's treatments could make a big winner of these stocks.

Via The Motley Fool

Where Will Biogen Be in 5 Years? ↗

October 20, 2022

Is this biotech an investment worth buying and holding today?

Via The Motley Fool

FDA Pushes Extends Review For Biogen's Amyotrophic Lateral Sclerosis Drug ↗

October 17, 2022

Via Benzinga

Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate ↗

October 17, 2022

Via Benzinga

This Beaten-Down ETF Is Still a Screaming Bear-Market Buy ↗

October 21, 2022

Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund.

Via The Motley Fool

Biogen Whale Trades For October 20 ↗

October 20, 2022

A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 12 strange trades.

Via Benzinga

Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients

October 20, 2022

Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which...

Via FinancialNewsMedia

10 Health Care Stocks Whale Activity In Today's Session ↗

October 19, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 18, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Biogen's Stock Pullback Offers a Second Chance

October 18, 2022

Biogen is positioned to become more diversified over time. A diminishing risk profile combined with emerging growth prospects make the stock attractive.

Via MarketBeat

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen

October 17, 2022

From Biogen Inc.

Via GlobeNewswire

This Is What Whales Are Betting On Biogen ↗

October 13, 2022

Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available...

Via Benzinga

Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts ↗

October 13, 2022

Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's.

Via Benzinga

Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity ↗

October 13, 2022

Even a percentage of the Alzheimer's market could mean $7 billion for Biogen.

Via Investor's Business Daily

GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®

October 13, 2022

From GoodRx

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022 ↗

October 13, 2022

Upgrades

Via Benzinga

Elliott Wave Technical Analysis: Biogen, Inc. - Thursday, Oct. 13 ↗

October 13, 2022

Biogen Inc. is moving as predicted, looking for this pullback to this support as we have had a huge gap to the upside.

Via Talk Markets

Is Seagen Stock a Buy Now? ↗

October 12, 2022

It's growing faster than competitors, but headwinds might soon bog it down.

Via The Motley Fool

Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients ↗

October 12, 2022

Via Benzinga

Does Biogen's Recent Win Make It a Must-Buy Stock? ↗

October 12, 2022

Will Biogen investors be let down again, or is this the real deal?

Via The Motley Fool

4 Biotech Stocks With Huge Incoming Catalysts ↗

October 12, 2022

All four of these drugmakers are expecting important FDA approval decisions over the next few months.

Via The Motley Fool

Biotech Stocks Well-Positioned For The Fourth Quarter ↗

October 12, 2022

The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.

Via Talk Markets

Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers ↗

October 10, 2022

Via Benzinga

These 7 Biotech Stocks Are Set to Boom in 2023 ↗

October 10, 2022

This article looks at seven biotech stocks that look like good options to move significantly higher in 2023

Via InvestorPlace

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Biogen Idec (NQ:BIIB)

All News about Biogen Idec

Starting at $3.75/week.

Subscribe Today